[바이오사 리포트] 삼성바이오로직스, 분할 첫 1분기 실적…수익성 입증

Samsung Biologics has proven its robust operational strength as a pure CDMO following its corporate split, achieving record profitability through maximized plant utilization. The upcoming integration of Plant 5 and the US-based Rockville facility marks a strategic shift toward global capacity expansion, positioning the company to capitalize on the BioSecure Act while managing initial overhead costs.